Role of Difucosylated Lewis Y Antigen in Outcome of Locally Advanced Cervical Squamous Cell Carcinoma Treated with Cisplatin Regimen

Abstract

In our cohort of LACSCC patients, the coexpression of CD44 and LeY was not associated with worse outcome. However, in the subgroup of patients receiving RCBC, LeY expression was correlated with shorter DFS and OS.

Role of CD44 in Chemotherapy Treatment Outcome: A Scoping Review of Clinical Studies

“…The results were categorized according to the effect of CD44 expression on chemotherapy treatment outcome. In summary, three studies reported a positive effect of increased CD44 expression on chemotherapy treatment outcome [ 22 , 23 , 24 ], thirteen studies reported no significant effect between CD44 expression and chemotherapy treatment outcome [ 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 ], and twenty-four studies reported a significant negative effect of increased CD44 expression on chemotherapy treatment outcome [ 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 ]. These studies are summarized in Table 1 , Table 2 and Table 3 , respectively.…”

“…Studies were further stratified based on the types of interventions. Nine studies involved chemotherapy as the only treatment [ 35 , 36 , 45 , 50 , 51 , 54 , 55 , 59 , 61 ], eight studies only involved radiochemotherapy [ 23 , 24 , 29 , 31 , 34 , 38 , 49 , 56 ], fifteen studies involved chemotherapy and surgery [ 25 , 26 , 27 , 30 , 33 , 39 , 41 , 42 , 44 , 46 , 47 , 52 , 53 , 57 , 58 ], and seven studies involved chemotherapy, radiotherapy, and surgery [ 22 , 28 , 37 , 39 , 43 , 48 , 60 ]. One study involved chemotherapy and hormonal therapy [ 40 ].…”

“…The effect of CD44 expression on chemotherapy treatment outcome categorized by the most common chemotherapy drugs used in studies included in this review is reported in Table 5 (5-fluorouracil [ 28 , 31 , 32 , 33 , 35 , 37 , 38 , 41 , 43 , 46 , 47 , 48 , 60 ], cisplatin [ 23 , 29 , 30 , 33 , 34 , 38 , 39 , 46 , 49 , 58 , 61 ] and docetaxel [ 34 , 38 , 46 , 50 , 58 , 61 ]). Other drugs used include adriamycin/doxorubicin [ 30 , 46 , 50 , 56 ], cyclophosphamide [ 35 , 43 , 46 , 50 , 56 ], cetuximab [ 29 , 38 , 49 ], paclitaxel [ 22 , 35 , 59 ], epirubicin [ 39 , 43 ], carboplatin [ 22 , 38 ], and etoposide [ 39 , 45 ].…”

“…Other drugs used include adriamycin/doxorubicin [ 30 , 46 , 50 , 56 ], cyclophosphamide [ 35 , 43 , 46 , 50 , 56 ], cetuximab [ 29 , 38 , 49 ], paclitaxel [ 22 , 35 , 59 ], epirubicin [ 39 , 43 ], carboplatin [ 22 , 38 ], and etoposide [ 39 , 45 ]. The following drugs are all mentioned by one article each: methotrexate [ 30 ], vinorelbine [ 34 ], leucovorin [ 37 ], bleomycin [ 39 ], idarubicin [ 45 ], ara-c [ 45 ], ifosfamide [ 30 ], thioguanine [ 45 ], amifostine [ 49 ], sunitinib [ 54 ], bevacizumab [ 55 ], anthracycline [ 57 ], taxane [ 57 ], capecitabine [ 58 ], temozolomide [ 24 ], trastuzumab [ 59 ], lapatinib [ 59 ], and capecitabine [ 58 ]. Elevent studies did not specify the chemotherapeutic drug or regime used to treat the patients [ 25 , 26 , 27 , 36 , 40 , 42 , 44 , 51 , 52 , 53 ].…”

Blood group‐related antigen Ley on human platelets and its involvement in platelet aggregation via a possible interaction with CD61

“…2 Like its family member CA19-9 (sialyl-Le a ), Le y is also a tumorrelated antigen, and most studies have focused on the expression of Le y and its interactions with partner proteins in various tumor types, as well as the effects of Le y on tumor cell adhesion, migration, invasion, proliferation, and drug resistance. [3][4][5][6][7][8] Although Le y is closely related to blood group antigens, there are very few reports revealing its association with blood cells. Jeyakanthan et al detected the expression of the Le y antigen on O, A 2 and A 2 B red blood cells (RBCs) for the purpose of improving organ transplantation compatibility.…”